The pharma company reported 29% growth in consolidated revenue to Rs 871 crore for the fourth quarter ended March 31, 2013 compared to the same quarter last fiscal. For the year ended March 31, 2013, consolidated net profit surged 52% to Rs 433 crore while revenue grew 19% to Rs 3,212 crore compared to the last fiscal ended March 31, 2012.
The board has recommended a dividend of Rs 7 per share and an additional Rs 10 per share for commemorating four decades of its business operations.
Further, the board of directors has proposed issue of bonus shares in the ratio one equity bonus share for each fully paid up equity share.
Over 500,000 shares were traded on both the stock exchanges so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%